Clinical and Immunological Factors Associated with Recommended Trough Levels of Adalimumab and Infliximab in Patients with Crohn’s Disease

MLA

Beatriz Orts, et al. “Clinical and Immunological Factors Associated with Recommended Trough Levels of Adalimumab and Infliximab in Patients with Crohn’s Disease.” Frontiers in Pharmacology, vol. 12, Jan. 2022. EBSCOhost, https://doi.org/10.3389/fphar.2021.795272.

APA

Beatriz Orts, Ana Gutierrez, Lucía Madero, Laura Sempere, Ruben Frances, & Pedro Zapater. (2022). Clinical and Immunological Factors Associated with Recommended Trough Levels of Adalimumab and Infliximab in Patients with Crohn’s Disease. Frontiers in Pharmacology, 12. https://doi.org/10.3389/fphar.2021.795272

Chicago

Beatriz Orts, Ana Gutierrez, Lucía Madero, Laura Sempere, Ruben Frances, and Pedro Zapater. 2022. “Clinical and Immunological Factors Associated with Recommended Trough Levels of Adalimumab and Infliximab in Patients with Crohn’s Disease.” Frontiers in Pharmacology 12 (January). doi:10.3389/fphar.2021.795272.